Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors, and potential policy changes. The company's recent financial performance, including a decline in net income and increased debt costs, underscores my conservative valuation approach.

DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation

More than 8,300 people joined the annual event to raise funds for Bridge of Life DENVER , Nov. 12, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced the success of its third annual Move It With Purpose (MIWP) event with more than 8,300 participants, including DaVita teammates, friends, family and key members of the kidney care community. The month-long initiative encourages physical activity — whether it's walking, running, swimming, bicycling or other activities — to benefit Bridge of Life, a nonprofit founded by DaVita to support the prevention and treatment of chronic disease globally.

DaVita's "Move It With Purpose" Sets Record Participation in Support of Global Health

DENVER , Nov. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at UBS Global Healthcare Conference 2024 on Tuesday, November 12, 2024 at 12:30 pm PST (3:30 pm EST). To view the live webcast, visit the UBS page here and create a free registration.

DaVita Inc. to Participate in UBS Global Healthcare Conference 2024

The company's profitability is going in the wrong direction for many investors.

Why DaVita Stock Withered on Wednesday

Kraft Heinz

This week marks a fire hose of earnings from several top Warren Buffett stock holdings. "Extraordinary business" Apple is on deck Thursday.

Two Warren Buffett Stocks Get Pounded, With Apple Earnings Due

DVA's robust Dialysis patient service revenues drives its third-quarter performance.

DaVita Stock Declines After Q3 Earnings Miss Estimates, Margins Up

DaVita Inc. (NYSE:DVA ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Nic Eliason - Group Vice President, Investor Relations Javier Rodriguez - Chief Executive Officer Joel Ackerman - Chief Financial Officer Conference Call Participants Andrew Mok - Barclays AJ Rice - UBS Pito Chickering - Deutsche Bank Lisa Clive - Bernstein Joanna Gajuk - Bank of America Ryan Langston - TD Cowen Justin Lake - Wolfe Research Operator Good evening. My name is Michelle and I will be your conference facilitator today.

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript

DaVita HealthCare (DVA) came out with quarterly earnings of $2.59 per share, missing the Zacks Consensus Estimate of $2.76 per share. This compares to earnings of $2.85 per share a year ago.

DaVita HealthCare (DVA) Q3 Earnings Miss Estimates

DaVita reported third-quarter profit that missed Wall Street estimates on Tuesday, hurt by high patient care costs.

DaVita misses third-quarter profit estimates on higher costs

DENVER , Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers.

DaVita Inc. 3rd Quarter 2024 Results

Fair Isaac

Eli Lilly

Micron Technology

Super Micro Computer

Tractor Supply

If you had to choose the best time to invest in the S&P 500 — it's the six months starting in November.

6 Stocks Dominate Market's 'Best 6 Months' — Starting This Week

The program aims to bring together a supportive network for people dealing with chronic health challenges for themselves and their loved ones DENVER , Oct. 28, 2024 /PRNewswire/ -- The DaVita Giving Foundation today announced an investment in the National Kidney Foundation (NKF)'s PEERS program, a program that provides social and emotional support for patients, care partners, and living donors through connections with mentors living through similar experiences. Prioritizing mental health in chronic disease care is essential, and mentorship can help provide people with support and comfort in a time when they might otherwise feel alone.

DaVita Emphasizes Commitment to Whole-Person Care with Investment in National Kidney Foundation PEERS Program

Improvement in RPT is likely to have boosted DaVita's top line in the third quarter.

DVA Q3 Estimates Unchanged Before Earnings: How to Play the Stock?

DENVER and SAN DIEGO , Oct. 23, 2024 /PRNewswire/ -- DaVita Clinical Research (DCR), a leading innovator in kidney care research and wholly owned subsidiary of DaVita Inc., will present the results of five innovative research projects at the American Society of Nephrology (ASN)'s annual Kidney Week meeting, which is currently underway in San Diego, CA. With a focus on improving racial equity in transplantation and key measures of clinical quality such as hospitalizations, DCR works to tackle pressing issues in nephrology that affect diverse populations.

DaVita Research Centers on Upstream CKD Management; Access & Equity during ASN's Kidney Week 2024

DaVita HealthCare (DVA) concluded the recent trading session at $163.16, signifying a +1% move from its prior day's close.

DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know

Nephrologists drive transformative outcomes through government's coordinated care program serving high-need patients DENVER , Oct. 22, 2024 /PRNewswire/ -- DaVita today announced performance year one clinical outcomes achieved in partnership with nearly 1,300 nephrologists across the U.S. through value-based care arrangements designed to enhance the lives of Medicare patients with kidney disease. As the broader health care community continues to explore value-based care arrangements to improve health outcomes in the U.S., DaVita commends the efforts from likeminded specialty care providers leading the movement.

DaVita celebrates kidney care community achievements in year one of largest-ever value-based care program

DENVER , Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide.

DaVita Appoints Jessica Hergenreter as Chief People Officer

In the most recent trading session, DaVita HealthCare (DVA) closed at $164.82, indicating a +0.15% shift from the previous trading day.

DaVita HealthCare (DVA) Advances But Underperforms Market: Key Facts

DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.

Can DaVita Stock Continue Its Bull Run After Doubling in a Year?

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing DaVita (DVA) Right Now?

TAMPA, Fla. , Oct. 11, 2024 /PRNewswire/ -- Following the widespread impact of Hurricane Milton, DaVita Kidney Care  dialysis centers have opened their doors to anyone in Florida needing treatment, including those who normally treat at other providers.

DaVita Opens its Doors to Anyone in Florida Needing Dialysis After Hurricane Milton

DENVER , Oct. 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, October 29, 2024, at 5:00 p.m. Eastern Time.

DaVita Inc. Schedules 3rd Quarter 2024 Investor Conference Call

DVA's strong performance and growth strategies, including patient-centric care and international expansion, position it well for continued success despite potential risks.

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

TAMPA , Oct. 8, 2024  /PRNewswire/ -- DaVita Kidney Care , a leading provider of kidney care services, has activated its emergency response plan in preparation for Hurricane Milton's landfall in Florida. DaVita's emergency response plans focus on proactively dialyzing thousands of patients ahead of the storm in more than 150 centers.

News for DaVita Stock (DVA)